Novel benzylimidazole derivatives of the formula: ##STR1## wherein X is halogen, nitro, alkyl, alkoxy, or halobenzyloxy;
m is an integer of 0 to 3;
Y is oxa, thia or substituted- or unsubstituted-imino;
R1 is alkyl, dialkylaminoalkyl, dibenzylaminoalkyl, 1-pyrrolidinyl, 2-imidazolin-2-yl, or a group of --(CH2)n--Z--Q
(wherein
n is an integer of 0 to 4;
Z is oxa, thia, or a single bond; and
Q is substituted- or unsubstituted-phenyl or thienyl) ##STR2## is methylene, 1-(1-imidazolyl)-1-methylmethylene, 1-(1-imidazolyl)-1-phenylmethylene, 1-phenylmethylene, or substituted or unsubstituted alkylidene;
the benzene ring of the above formula being optionally condensed with another benzene ring
with the proviso that when ##STR3## is methylene said benzene ring is condensed with another benzene ring, and acid addition salts thereof which are useful as an antimycotic drug or agricultural fungicide.
|
1. A compound of the formula: ##STR71## wherein X is halogen, nitro, C1 to C5 alkyl, C1 to C5 alkoxy or halobenzyloxy;
m is an integer of 0 to 3; Y is oxa, thia or imino optionally substituted by C1 to C5 alkanoyl, C1 to C5 halo-alkanoyl or C1 to C5 alkyl; R1 is C1 to C5 alkyl, C3 to C10 dialkylaminoalkyl, C15 to C20 dibenzylamino-alkyl, 1-pyrrolidinyl, 2-imidazolin-2-yl or a group of the formula --(CH2)n --Z--Q wherein n is an integer of 0 to 4, Z is oxa, thia or a single bond and Q is phenyl or thienyl optionally substituted by 1 to 3 members selected from the group consisting of halogen, nitro, C1 to C5 alkyl and C1 to C5 alkoxy; and R4 is C1 to C5 alkylidene optionally substituted by phenyl,
the benzene ring in the above formula being optionally condensed with another benzene ring, or a pharmaceutically acceptable acid addition salt thereof. 3. The compound 1-[1-(2-(3-chlorobenzyloxy)phenyl)vinyl]imidazole.
4. The compound 1-[1-(2-(4-chlorobenzyloxy)phenyl)vinyl]imidazole.
5. The compound 1-[1-(2-(phenethyloxy)phenyl)vinyl]imidazole.
6. The compound 1-[2-(4-chlorobenzyloxy)phenyl]-1,1-bis(1-imidazolyl)-1-phenylmethane.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This invention relates to novel benzylimidazole derivatives useful as an antimycotic drug or agricultural fungicide. Such compounds are, for example, disclosed in Japanese Unexamined Patent Publication No. 50-148357 and the European Journal of Medicinal Chemistry 14, No. 3, pp 227-230, 231-237, 243-245 (1979). But the compounds of the following formula (I) are novel. ##STR4## , wherein X is halogen, nitro, C1 to C5 alkyl, C1 to C5 alkoxy or halo-benzyloxy;
m is an integer of 0 to 3;
Y is oxa, thia or imino optionally substituted by C1 to C5 alkanoyl, C1 to C5 halo-alkanoyl or C1 to C5 alkyl;
R1 is C1 to C5 alkyl, C3 to C10 dialkylaminoalkyl, C15 to C20 dibenzylaminoalkyl, 1-pyrrolidinyl, 2-imidazolin-2-yl, or a group of --(CH2)n--Z--Q
(wherein
n is an integer of 0 to 4;
Z is oxa, thia, or a single bond;
Q is phenyl or thienyl optionally substituted by 1 to 3 members selected from halogen, nitro, C1 to C5 alkyl, and C1 to C5 alkoxy); ##STR5## is methylene, 1-(1-imidazolyl)-1-methylmethylene, 1-(1-imidazolyl)-1-phenylmethylene, 1-phenylmethylene, or C1 to C5 alkylidene optionally substituted by phenyl;
the benzene ring of the above formula being optionally condensed with another benzene ring
with the proviso that when ##STR6## is methylene said benzene ring is condensed with another benzene ring, and pharmaceutically acceptable acid addition salts thereof.
In the above general formula, halogen means chloro, bromo, fluoro and iodo, preferably chloro. C1 and C5 Alkyl means methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, pentyl, isopentyl, and the like and C1 to C5 alkoxy means methoxy, ethoxy, propoxy, isopropoxy, butyloxy, sec-butyloxy, pentyloxy, isopentyloxy, and the like. C1 to C5 Alkanoyl means formyl, acetyl, propionyl, butyryl, and the like. C3 to C10 Dialkylaminoalkyl means dimethylaminoethyl, diethylaminoethyl, dipropylaminobutyl, methylethylaminoethyl, and the like. C1 to C5 Alkylidene means methylene, ethylidene, propylidene, isopropylidene, butylidene, pentylidene, and the like.
Compounds (I) can be easily converted to the corresponding pharmaceutically acceptable acid addition salts, which are included within the scope of this invention. Representative acids which can form the pharmaceutically acceptable salts are organic acids such as acetic acid, citric acid, tartaric acid, methanesulfonic acid, malic acid, succinic acid, oxalic acid, salicyclic acid, or the like and inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or the like.
Compounds (I) may be prepared according to the following scheme: ##STR7## (wherein M is hydrogen or alkali metal;
A is halogen or an ester residue;
B and D each is hydrogen or alkyl;
and X, m, Y, R1, R2 and R3 each has the same significance as given earlier)
(First Step)
This process may be carried out by reacting Compound (II) with Compound (III) in the presence of a base in an inert solvent at room temperature or under heating. Representative bases are sodium hydroxide, potassium hydroxide, sodium hydride, sodium amide, potassium amide, sodium ethoxide, potassium carbonate, and the like. Representative inert solvents are dimethylformamide, benzene, methanol, chloroform, dioxane, tetrahydrofuran, acetone, and the like.
The starting compound (II) is available, for example, by treating the ketone (IV) with N,N'-thionyldiimidazole or N,N'-carbonyldiimidazole for imidazole formation. The reaction is carried out in an inert solvent such as methylene chloride, chloroform, tetrahydrofuran, dioxane, benzene, acetonitrile, or 1,2-dichloroethane at room temperature or under cooling.
(Second Step)
The reaction of the starting compound (IV) with the compound (III) may be carried out in the same manner as in the First Step. Then the intermediate (V) is subjected to the imidazole formation in the same manner as in the above preparation of the starting compound (II).
IV. Effect
Compounds (I) and the pharmaceutically acceptable salts thereof prepared in this invention exhibit excellent antimycotic activities and are useful as an antimycotic drug for humans and animals.
Minimum Inhibitory Concentration (MIC, μ/ml) in vitro of some typical Compounds (I) are indicated in the following Table 1. The compound numbers correspond to the structure of the products prepared in the respective numbered Examples.
| TABLE 1 |
| ______________________________________ |
| MIC Values (γ/ml) |
| Fungi |
| Compound Aspergillus |
| Candida Trichophyton |
| No. fumigates albicans M-9 |
| asteroides |
| ______________________________________ |
| 1 3.1 6.2 <0.1 |
| 7 1.6 100.0 <0.1 |
| 8 1.6 25.0 50.0 |
| 13 1.6 6.2 <0.1 |
| 17 3.1 3.1 <0.1 |
| 22 1.6 6.2 <0.1 |
| 28 6.2 12.5 <0.1 |
| 34 6.2 50.0 1.6 |
| 39 0.4 6.2 <0.1 |
| 40 12.5 25 1.6 |
| 41 6.2 3.1 <0.1 |
| 42 3.1 12.5 3.1 |
| 43 1.6 12.5 3.1 |
| 44 3.1 12.5 3.1 |
| 45 6.2 25 3.1 |
| 46 6.2 25 3.1 |
| 47 6.2 12.5 1.6 |
| 62 0.8 25.0 <0.1 |
| 66 6.2 12.5 0.2 |
| 67 6.2 6.2 0.2 |
| 68 6.2 12.5 3.1 |
| 69 12.5 25 1.6 |
| ______________________________________ |
Compounds (I) and their acid addition salts exhibit excellent antifungal activities against various phytopathogenic fungi and soil borne pathogens and are useful as agricultural fungicides.
(1) Test Method
A seed of cucumber (cultivar:Matsukaze) was sown in a vinyl chloride-cup of 9 cm in diameter containing soil in a greenhouse and cultivated. At the primary leaf stage, 2.5 ml each of the solution containing a prescribed concentration of the test compound was applied over the above cucumber, which was kept at 25° to 26°C in 80% humidity for 24 hours. A suspension of Botrytis cinerea spores was inoculated onto the leaves at five spots per leaf and the leaves were kept at 80°C in 95% humidity for 72 hours.
(2) Results
The results are shown by percent disease control (%) calculated from the diseased degree according to the following formula. ##EQU1##
The compounds numbered in the following Table 2 each have the same structure as that of the compounds in the corresponding numbered Examples.
| TABLE 2 |
| ______________________________________ |
| Compd. Concentration Percent Disease |
| No. (ppm) Diseased Degree |
| Control (%) |
| ______________________________________ |
| 1 500 0 100 |
| 3 " " " |
| 6 " " " |
| 7 " 40 60 |
| 8 " 0 100 |
| 15 " " " |
| 17 " " " |
| 24 " " " |
| 27 " " " |
| 34 " " " |
| 61 " " " |
| 62 " " " |
| un- |
| treated -- 100 0 |
| ______________________________________ |
| (Note)- |
| Diseased degrees were calculated according to the subsequent |
| Disease condition |
| Marks Numbers examined |
| ______________________________________ |
| Largely faded lesions |
| formed at inoculated |
| 20 a |
| parts |
| Back of the inoculated |
| leaf faded 10 b |
| Back of the inoculated |
| leaf slightly faded |
| 5 c |
| No disease 0 d |
| ______________________________________ |
| ##STR8## |
(1) Test Method
A seed of cucumber (cultivar:Matsukaze) was sown on a vinyl chloride-cup of 9 cm in diameter in a greenhouse containing soil and cultivated. At the primary leaf stage, 2.5 ml each of the solution containing a prescribed concentration of the test compound was applied over the above cucumber, which was kept at 25° to 26°C in 80% humidity for 24 hours. A suspension of Colletotrichum lagenarium spores was inoculated onto the above leaves at five spots per leaf and the leaves were kept at 25°C in 95% humidity for 1 day and at 25°C in 75 to 80% humidity for 6 days.
(2) Results
Percent disease control (%) was calculated as mentioned in the above test 1.
| TABLE 3 |
| ______________________________________ |
| Compd. Concentration Percent Disease |
| No. (ppm) Diseased Degree |
| Control (%) |
| ______________________________________ |
| 46 500 20 80 |
| 58 " 0 100 |
| un- |
| treated -- 100 0 |
| ______________________________________ |
(1) Test Method
A seed of cucumber (cultivar:Matsukaze) was sown in a vinyl chloride-cup of 9 cm in diameter containing soil in a greenhouse and cultivated. At the primary leaf stage, 5 ml each of a solution of the test compound in a prescribed concentration was applied over the above cucumber, which was kept at 25° to 26°C for 1 day. Primary leaves of cucumber previously infected by pathogenic fungi of the powdery mildew (Shpaerotheca fuliginea) were taken and those having lesions covered with spores were cut out in 1 square centimeter pieces, which were stuck to the primary leaves in the cups for inoculation, four plots per leaf. The above treated leaves were kept at 25° to 26°C for 10 days.
The spore formation on the inoculated plots was observed by a microscope.
Standard of the evaluation:
(+): Formation of many spores and hypae observed on the inoculated plots
(-): Neither infected spots nor spore formation observed on the inoculated plots
(2) Results
| ______________________________________ |
| Compd. No. Concentration (ppm) |
| Diseased Degree |
| ______________________________________ |
| 5 500 - |
| 21 " - |
| 36 " - |
| 78 " - |
| 80 " - |
| untreated -- + |
| ______________________________________ |
(1) Test Method
Seedlings of rice plant (cultivar:Aichi-asahi) reared in a greenhouse for 10 days were transplanted in a vinyl chloride-cup of 9 cm in diameter. A solution of the test compound at a prescribed concentration was applied to the above rice plants 14 days after the transplanting. One day after the application, a spore suspension of pathogenic fungi of rice plant blast (Pyricularia oryzae) was sprayed on the leaf blades of the seedlings, which were kept at 28°C in 98% humidity for 24 hours and at 28°C in 90% humidity for 7 days in a greenhouse. The number of infected spots on the inoculated leaves was observed.
(2) Results
The results are shown by percent disease control which was calculated according to the following formula:
| ______________________________________ |
| Percent Disease Control (%) = |
| ##STR9## |
| Compd. Concentration |
| Number of Percent Disease |
| No. (ppm) Spots Control (%) |
| ______________________________________ |
| 23 500 271 89.5 |
| 28 " 45 98.3 |
| 36 " 25 99.0 |
| 78 " 99 96.2 |
| un- |
| treated -- 2589 0 |
| ______________________________________ |
Compounds (I) or the salts thereof may be applied in a wide variety of oral or parenteral dosage forms solely or in admixture with additives such as diluents, carriers, dispersants and the like. The pharmaceutical compositions may be in the form of solutions, suspensions, powders, granules, tablets, injections, ointments, tinctures, and the like. The formulations may be dispensed in a conventional manner. For example, Compounds (I) may be administered at a dose of 100 to 2000 mg per day for enteral application.
Further, compounds (I) and the salts thereof exhibit an excellent control effect against the following phyto-pathogenic fungi and other soil borne pathogens.
Rice plant: blast, damping-off, leaf spot
Wheat and barley: stem rust, loose smut, powdery mildew
Pear: red spot, scab, Alternaria leaf spot
Grape: gray rust, ripe rot, downy mildew, leaf spot, white rot, gray mold, powdery mildew
Apple: Alternaria leaf spot, canker, black spot, red spot, blossom blight
Peach: brown rot
Cucumber: downy mildew, anthracnose, sclerotinia rot, gray mold, powdery mildew
Green pepper: powdery mildew
Tobacco: brown spot, powdery mildew
Compounds (I) or the salts thereof may be formed into wettable powders, granules, powders, emulsions, tablets, aerosols, fumigations, oils, and the like solely or in admixture with additives or carriers ordinarily employed in agricultural fungicides. Compounds (I) may be applied to plants at a dose of 0.5 to 100 g per are.
The following examples are provided to further illustrate this invention.
To a solution of 60 g of imidazole in 300 ml of dry methylene chloride is added 26.2 g of thionyl chloride, and the mixture is stirred at room temperature for 10 minutes, mixed with 20 g of Compound (1), and stirred at room temperature for 1.5 hours. The reaction mixture is mixed with ice water and extracted with methylene chloride. The organic layer is washed with water, dried over Glauber's salt, and concentrated. The residue is dissolved in a mixture of 5% methanol and methylene chloride and chromatographed on a column of silica gel. The eluate is concentrated and the residue is washed with a mixture of ethyl acetate and isopropyl ether to give 25.8 g of Compound (2).
mp. 150°-151°C
IR: νmaxNujol 3300-2100, 2570, 1630 cm-1.
(step b)
To a solution of the sodium salt of Compound (2) prepared from 500 mg of Compound (2), 164 mg of 60% sodium hydride and 5 ml of dry dimethylformamide is added 828 mg of p-chlorobenzyl bromide, and the mixture is stirred at room temperature for 15 minutes. The reaction mixture is mixed with ice water and extracted with methylene chloride. The organic layer is washed with water, dried over Glauber's salt, and concentrated. The residue is chromatographed on a column of silica gel, which is eluted with a mixture of 2% methanol and methylene chloride. The eluate is collected and mixed with a mixture of hydrochloric acid and ethanol, and the mixture is concentrated. The residue is crystallized from a mixture of ethyl acetate and ether and recrystallized from a mixture of methanol and ethyl acetate to give 345 mg of Compound (3) hydrochloride.
mp. 180.5°∼181°C (decomposition)
IR: νmaxNujol 2600 2300, 1649 cm-1.
To a solution of N,N'-thionyldiimidazole prepared from 2.95 g of imidazole and 1.29 g of thionyl chloride in 15 ml of dry methylene chloride is added 2.0 g of Compound (4), and the mixture is extracted with methylene chloride. The organic layer is washed with water, dried over Glauber's salt, and concentrated. The residue is chromatographed on a column of silica gel, which is eluted with methylene chloride to recover 750 mg of unreacted Compound (4). The eluate from 1% methanol-methylene chloride to 2% methanol-methylene chloride is collected and concentrated, and the resulting residue is crystallized from ethanolic hydrochloric acid and recrystallized from methanol-ethyl acetate-ether to give 310 mg of Compound (5).
mp. 153°-163°C
To a solution of 1 g of Compound (2) in 5 ml of dimethylformamide is added 322 mg of a 60% suspension of sodium hydride in mineral oil with ice-cooling, and the mixture is stirred for 5 minutes, mixed with 1.14 g of methyliodide, and stirred at room temperature for 10 minutes. The reaction mixture is diluted with ice water and extracted with ether. The organic layer is washed with water, dried over Glauber's salt, and concentrated. The residue is chromatographed on a column of silica gel and eluted with 37% methanol-methylene chloride. The eluate is concentrated, and the residue is crystallized from hydrochloric acid-ethanol and recrystallized from methanol-acetic acid to give 520 mg of Compound (6).
mp. 190°-195°C
Elemental Analysis (for C12 H12 ON2.HCl): Calcd(%): C, 60.89; H, 5.54; N, 11.84; Cl, 14.98; Found(%): C, 60.78; H, 5.52; N, 11.73; Cl, 15.02.
The following compounds are prepared in the same manner as mentioned in the above Examples.
| __________________________________________________________________________ |
| ##STR13## |
| Ex. mp (°C.) |
| No. |
| m X Y R1 R2 |
| R3 |
| Salt or |
| __________________________________________________________________________ |
| IR |
| 4 O -- 2-O CH3 CH3 |
| Im -- 164-165 |
| 5 " " " |
| ##STR14## Ph Im " 155-156 |
| 6 " " " C2 H5 |
| CH2 HCl . 1/2H2 O |
| 159-162 |
| 7 " " " n-C3 H7 |
| " " 146-148 |
| 8 " " " n-C4 H9 |
| " -- oily product |
| ν film |
| 1638 |
| cm-1 |
| 9 " " " (CH2)3N(CH3)2 |
| " 1/4CH3 OH |
| oily product |
| νfilm |
| 1632 |
| cm-1 |
| 10 " " " CH2 Ph " HCl 154-156 |
| 11 " " " |
| ##STR15## " -- 85-86 |
| 12 " " " " " HCl 180.5-181 |
| 13 " " " |
| ##STR16## " " 148.5-149 |
| 14 " " " |
| ##STR17## " " 161-163 |
| 15 " " " |
| ##STR18## " " 172-174 |
| 16 " " " |
| ##STR19## " -- 94-94.5 |
| 17 " " " |
| ##STR20## " HCl 180-183 |
| 18 " " " |
| ##STR21## " " 138-147 |
| 19 " " " |
| ##STR22## " -- oily product |
| νfilm |
| 1639 cm-1 |
| 20 " " " |
| ##STR23## " " oily product |
| νfilm |
| 1630 cm-1 |
| 21 " " " |
| ##STR24## " HCl 139-142 |
| 22 " " " |
| ##STR25## " " 165-172 |
| 23 " " " (CH2)2 Ph |
| " (COOH)2 |
| 122.5-124.5 |
| 24 " " " (CH2)2N(C2 H5)2 |
| " 2(COOH)2 |
| 80-81 |
| 25 " " " (CH2)2N(CH2 Ph)2 |
| " -- oily product |
| νfilm |
| 1634 |
| cm-1 |
| 26 " " " |
| ##STR26## " 2(COOH)2 |
| 153.5-155 |
| 27 " " " (CH2)2OPh |
| " HCl 158-160 |
| 28 " " " |
| ##STR27## " " 140-142 |
| 29 " " " (CH2)3Ph |
| " -- oily product |
| νfilm |
| 1639 |
| cm-1 |
| 30 " " " (CH2)3N(CH3)2 |
| " 2(COOH)2 |
| 125-127 |
| 31 " " " (CH2)3N(C2 H5)2 |
| " " 146.5-147.5 |
| 32 " " " |
| ##STR28## " -- oily product |
| νfilm |
| 1635 cm-1 |
| 33 " " " |
| ##STR29## " HCl 138-140 |
| 34 " " " CH3 CH ∼ CH3 * |
| -- oily product |
| νfilm |
| 1660 |
| cm-1 |
| 35 " " " CH2 Ph CH ∼ CH3 *** |
| " oily product |
| ν film |
| 1659 |
| cm-1 |
| 36 " " " |
| ##STR30## CH ∼ CH3 * |
| HCl 175-177 |
| 37 " " " |
| ##STR31## CH ∼ CH3 ** |
| " 185-187 |
| 38 " " " |
| ##STR32## CH ∼ CH3 *** |
| -- oily product |
| νfilm |
| 1658 cm-1 |
| 39 " " " |
| ##STR33## CH ∼ CH3 *** |
| HCl 156-158 |
| 40 " " " CH2 Ph C(CH3)2 |
| -- oily product |
| νfilm |
| 1665 |
| cm-1 |
| 41 " " " |
| ##STR34## " HCl 137-138 |
| 42 " " " |
| ##STR35## " -- 62.5-64 |
| 43 " " " |
| ##STR36## " " 100-102 |
| 44 " " " |
| ##STR37## " " 100-101 |
| 45 " " " |
| ##STR38## " " 58-60 |
| 46 " " " (CH2)2OPh |
| " " 76-78 |
| 47 " " " |
| ##STR39## " " oily product |
| νfilm |
| 1670 cm-1 |
| 48 1 4-Cl " CH3 CH2 HCl . 1/2H2 O |
| 193-196 |
| 49 " " " |
| ##STR40## " -- 132-133 |
| 50 " " " (CH2)3N(CH3)2 |
| " 2(COOH)2 |
| 142-143.5 |
| 51 " 5-Cl " |
| ##STR41## H Ph -- 115-116 |
| 52 " " " CH2 Ph Ph Im -- 166.5-167 |
| 53 " " " |
| ##STR42## " " -- 187-188 |
| 54 " " " |
| ##STR43## " " -- 189-191 |
| 55 " " " |
| ##STR44## " " -- 165-167 |
| 56 " " " |
| ##STR45## " " -- 172-173.5 |
| 57 " " " CH2 Ph CH2 HCl . 1/10H2 O |
| 174-175 |
| 58 " " " |
| ##STR46## " " 188-190 |
| 59 " " " |
| ##STR47## " HCl . H2 O |
| 172-174 |
| 60 " " " |
| ##STR48## " HCl 165-172 |
| 61 " " " CH3 " " 239 |
| 62 " " " n-C3 H7 |
| " " 178-181 |
| 63 " " " CH2 Ph CH ∼ CH3 *** |
| " 132-134 |
| 64 " " " |
| ##STR49## " " 211-212 |
| 65 " " " |
| ##STR50## " " 170-174 |
| 66 " " " CH2 Ph C(CH3)2 |
| " 192-193.5 |
| 67 " " " |
| ##STR51## " " 201-203 |
| 68 " " " |
| ##STR52## " " 193-194 |
| 69 " " " |
| ##STR53## " -- 106-108 |
| 70 " " " |
| ##STR54## " 1/3H2 O |
| oily product |
| νfilm |
| 1668 cm-1 |
| 71 " " " CH3 CH ∼ Ph |
| -- 118-118.5 |
| 72 " " " CH2 Ph CH ∼ C2 H5 *** |
| -- 158.5-159.5 |
| 73 " " " |
| ##STR55## " HCl 220-222 |
| 74 " " " |
| ##STR56## " HCl 166-167 |
| 75 " " " (CH2)3N(CH3)2 |
| CH2 2(COOH)2 |
| 105.5-107 |
| 76 " |
| ##STR57## " |
| ##STR58## " HCl 193-195 |
| 77 2 3,5-Cl " CH2 Ph " " 170-172 |
| 78 " " " |
| ##STR59## " " 155-165 |
| 79 " " " |
| ##STR60## " " 170-171 |
| 80 " " " |
| ##STR61## " " 150-153.5 |
| 81 " " " |
| ##STR62## " 2(COOH)2 . 1/3H2 |
| 153-154 |
| 82 " " " (CH2)3N(CH3)2 |
| " 2(COOH)2 |
| 119-120 |
| 83 0 -- 3-O |
| ##STR63## " 1/2H2 O |
| oily product |
| νfilm : |
| 1638 cm-1 |
| 84 " " 2-NH |
| " CH3 |
| Im -- 143.5-144 |
| 85 " " " " CH2 " 147-148 |
| 86 " " |
| ##STR64## |
| " " " 101-101.5 |
| 87 1 5-Cl 2-O (CH2)3N(CH3)2 |
| C(CH3)2 |
| 2(COOH)2 . CH3 |
| 101-104 |
| 88 |
| ##STR65## " |
| ##STR66## H H HCl 166-167 |
| 89 |
| ##STR67## " " " " -- 154-156 |
| 90 |
| ##STR68## " " " " " 142-143 |
| 91 " " " CH2 -- 120-121 |
| __________________________________________________________________________ |
| (Note)- |
| The meanings of abbreviations are as |
| Ph = phenyl |
| Im = imidazolyl |
| i-Pr = isopropyl |
| Tr = trifluoroacetyl |
| *means that methyl (ethyl, phenyl) group takes cisform to imidazolyl |
| group. |
| **means that methyl (ethyl, phenyl) group takes transform to imidazolyl |
| group. |
| ***means the mixture of cis and transform. |
Compound (2) (500 mg) is hydrogenated in 14% hydrochloric acid-methanol (5 ml) in the presence of platinum oxide in a hydrogen stream. After the absorption of 1 mole of hydrogen, the reaction is stopped. The reaction is filtered and the filtrate is concentrated. The residue is mixed with aqueous sodium hydrogencarbonate solution and extracted with methylene chloride. The organic layer is washed with water, dried over Glauber's salt and concentrated. The residue is crystallized from ethyl acetate-isopropyl ether to give Compound (7) (456 mg). mp. 170.5°∼172°C
To a solution of N,N'-thionyldiimidazole prepared from imidazole (4.12 g), thionyl chloride (1.8 g), and dry methylene chloride (20 ml) is added Compound (1) (2 g), and the mixture is allowed to stand at room temperature overnight. The reaction mixture is mixed with ice-water and extracted with methylene chloride. The organic layer is washed with water, dried, and concentrated. The residue is washed with ethyl acetate-ether to give Compound (9) (2.72 g).
mp. 183°∼193°C
Hydrochloride of Compound (9) (2HCl.H2 O)
mp. 124°∼127°C
The preparation for fungicides are as follows:
A mixture of Compound (3) hydrochloride prepared in Example 1 (5 weight parts), clay (85 weight parts), and talc (10 weight parts) is pulverized and formulated into a dust.
A mixture of a compound prepared in Example 8 (50 weight parts), diatomaceous earth (45 weight parts), and calcium alkylbenzenesulfonate (2.5 weight parts) is pulverized, admixed, and formulated into a wettable powder.
A mixture of the compound prepared in Example 27 (30 weight parts), xylene (60 weight parts), and polyoxyethylene alkyl aryl ether (10 weight parts) is admixed and formulated into an emulsion.
A mixture of the compound prepared in Example 3 (5 weight parts), clay (85 weight parts), and talc (10 weight parts) is pulverized and formulated into a dust.
A mixture of the compound prepared in Example 48 (50 weight parts), diatomaceous earth (45 weight parts), and calcium alkylbenzenesulfonate (2.5 weight parts) is pulverized, admixed, and formulated into a wettable powder.
A mixture of the compound prepared in Example 7 (30 weight parts), xylene (60 weight parts), and polyoxyethylene alkyl aryl ether (10 weight parts) is admixed and formulated into an emulsion.
The compound prepared in Example 62 (10 weight parts) is dissolved in water (90 weight parts) to give a solution.
The preparations for antimycotics are as follows:
| ______________________________________ |
| Cream: The compound prepareed in Example 13 |
| 10 g |
| Bees wax 100 g |
| Cetyl alcohol 50 g |
| 2-Octyldodecanol 50 g |
| Propylene glycol 300 g |
| Mixture (1:1 w/w) of sorbitan mono- |
| stearate and polyoxyethylene sorbitan |
| 50 g |
| monostearate |
| Mixture (1.9:0.2 w/w) of butyl paraben |
| and methyl paraben 2 g |
| Mixture (0.06:1.25:9 w/w/w) of phosphoric |
| acid, sodium hydroxide and monosodium |
| 10 g |
| phosphate dihydrate |
| Distilled water 428 g |
| 1000 g |
| ______________________________________ |
| ______________________________________ |
| Gel: Nitrate of the compound prepared in |
| Example 13 10 g |
| Carbopol 940 (carboxyvinyl polymer) |
| 15 g |
| Ethanol 100 g |
| Propylene glycol 650 g |
| Triisopropanolamine 10 g |
| Distilled water 215 g |
| 1000 g |
| ______________________________________ |
Takahashi, Toshio, Matsumoto, Hiroshi, Ogata, Masaru, Watanabe, Yoshihachi, Tawara, Katsuya
| Patent | Priority | Assignee | Title |
| 4459412, | Dec 05 1980 | SHIONOGI & CO , LTD | 1-Benzylimidazole derivatives |
| 4584311, | Jan 09 1984 | Mitsui Toatsu Chemicals, Inc. | Microbiocidal 1-[1-(alkoxyphenyl)vinyl]-1H-imidazoles |
| 4755526, | Jun 18 1984 | Eli Lilly and Company | Method of inhibiting aromatase |
| 4780471, | Jul 01 1986 | Shionogi & Co., Ltd. | Fungicidal azole derivatives |
| 4894381, | Jun 27 1987 | Bayer Aktiengesellschaft | Microbicidal (azolyl-vinyl)-phenol alkenyl ethers |
| 5216007, | Oct 01 1980 | Rohm and Haas Company | Substituted ethylene imidazole and triazoles |
| 5256683, | Dec 29 1988 | Rhone-Poulenc Agrochimie | Fungicidal compositions containing (benzylidene)-azolylmethylcycloalkane |
| 5380743, | Dec 29 1988 | Rhone-Poulenc Agrochimie | Fungicidal compositions containing (benzylidene)-azolymethylcycloalkane |
| 5466704, | Feb 16 1991 | E. R. Squibb & Sons, Inc. | N-substituted imidazole and benzimidazole derivatives useful as angiotenson II antagonists |
| 5639918, | Dec 29 1988 | Rhone-Poulenc Agrochimie | Intermediate compounds useful in the preparation of fungicidal compositions containing (benzylidene)-azolylmethyclycloalkane |
| 5965743, | Apr 27 1994 | Nippon Soda Co., Ltd. | N-substituted imidazol derivative |
| Patent | Priority | Assignee | Title |
| 3709901, | |||
| 3985766, | |||
| 4006243, | Apr 11 1974 | Schering Aktiengesellschaft | Amino-, mercapto- and -oxy-substituted-phenyl and -phenalkyl imidazoles |
| 4226878, | Jun 13 1978 | Kissei Pharmaceutical Co., Ltd.; ONO Pharmaceutical Co., Ltd. | Imidazole derivative |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jun 06 1980 | Shionogi & Co., Ltd. | (assignment on the face of the patent) | / | |||
| Nov 11 1981 | OGATA, MASARU | SHIONOGI & CO , LTD | ASSIGNMENT OF ASSIGNORS INTEREST | 003944 | /0679 | |
| Nov 11 1981 | TAWARA, KATSUYA | SHIONOGI & CO , LTD | ASSIGNMENT OF ASSIGNORS INTEREST | 003944 | /0679 | |
| Nov 16 1981 | WATANABE, YOSHIHACHI | SHIONOGI & CO , LTD | ASSIGNMENT OF ASSIGNORS INTEREST | 003944 | /0679 | |
| Nov 19 1981 | MATSUMOTO, HIROSHI | SHIONOGI & CO , LTD | ASSIGNMENT OF ASSIGNORS INTEREST | 003944 | /0679 | |
| Nov 25 1981 | TAKAHASHI, TOSHIO | SHIONOGI & CO , LTD | ASSIGNMENT OF ASSIGNORS INTEREST | 003944 | /0679 |
| Date | Maintenance Fee Events |
| Date | Maintenance Schedule |
| May 04 1985 | 4 years fee payment window open |
| Nov 04 1985 | 6 months grace period start (w surcharge) |
| May 04 1986 | patent expiry (for year 4) |
| May 04 1988 | 2 years to revive unintentionally abandoned end. (for year 4) |
| May 04 1989 | 8 years fee payment window open |
| Nov 04 1989 | 6 months grace period start (w surcharge) |
| May 04 1990 | patent expiry (for year 8) |
| May 04 1992 | 2 years to revive unintentionally abandoned end. (for year 8) |
| May 04 1993 | 12 years fee payment window open |
| Nov 04 1993 | 6 months grace period start (w surcharge) |
| May 04 1994 | patent expiry (for year 12) |
| May 04 1996 | 2 years to revive unintentionally abandoned end. (for year 12) |